- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CMS Wasted $250 Million With Outdated Drug Pricing Estimates
CMS wasted nearly $251 million in taxpayer dollars on infusion drugs in just 18 months by using outdated drug pricing estimates, which drove up the cost of prescription injectable drugs for an aging baby boomer population.
Ignoring previous cost-cutting recommendations from its own watchdogs, CMS wasted nearly $251 million in taxpayer dollars on infusion drugs in just 18 months by using outdated drug pricing estimates, which drove up the cost of prescription injectable drugs for an aging baby boomer population.
In addition, roughly $50 million of the overpayments could have reduced coinsurance costs for Medicare and Medicaid beneficiaries using infusion drugs to treat diseases like cancer, diabetes, congestive heart failure, and rheumatoid arthritis, according to a new report.
Watchdog groups say that the report released by HHS' Office of Inspector General highlights a troubling culture of federal indifference at the taxpayers’ expense.
Read more at Washington Times: http://bit.ly/1DHajth
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
